View Exam | PowerPak

1. In patients with melanoma, ipilimumab has the potential to _______________.

A. engage tumor cell growth factors B. prevent tumor cell division C. block enzymes essential to DNA replication D. deactivate immune suppressive pathways

2. NP is a stage IV melanoma patient with good performance status whose disease has metastasized to the lung and liver. The BEST treatment choice for NP would be which of the following?

A. Nivolumab and ipilimumab B. Dacarbazine and IL-2 C. Ipilimumab and dacarbazine D. Pembrolizumab and vemurafenib

3. Which of the following treatments offers a survival advantage in patients with melanoma?

A. IL-2 B. Dacarbazine C. Nivolumab D. Crizotinib

4. Which of the following therapies is the BEST choice for non-small–cell lung cancer patients with progressive disease, good performance status, and EFGR-positive tumors?

A. Ipilimumab B. Nivolumab C. Bevacizumab and pembrolizumab D. Docetaxel

5. Which of the following BEST describes a partial response to nivolumab therapy?

A. At least a 30% decrease in index lesion without new lesions B. At least a 50% decrease in signal lesion size C. The disappearance of most signal lesions D. No new lesions on 2 consecutive observations

6. EB has been taking nivolumab for her melanoma. She has developed acute hepatitis, and her most recent laboratory results show that her aspartate transaminase levels are more than 7 times the upper limit of normal. Which of the following strategies would you MOST likely recommend to manage EB's adverse events?

A. Permanent discontinuation of treatment B. Switching her to pembrolizumab treatment C. Introducing corticosteroids while tapering nivolumab D. Continuing her treatment with regular aminotransferase monitoring

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In patients with melanoma, ipilimumab has the potential to _______________.

2. NP is a stage IV melanoma patient with good performance status whose disease has metastasized to the lung and liver. The BEST treatment choice for NP would be which of the following?

3. Which of the following treatments offers a survival advantage in patients with melanoma?

4. Which of the following therapies is the BEST choice for non-small–cell lung cancer patients with progressive disease, good performance status, and EFGR-positive tumors?

5. Which of the following BEST describes a partial response to nivolumab therapy?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In patients with melanoma, ipilimumab has the potential to _______________.

2. NP is a stage IV melanoma patient with good performance status whose disease has metastasized to the lung and liver. The BEST treatment choice for NP would be which of the following?

3. Which of the following treatments offers a survival advantage in patients with melanoma?

4. Which of the following therapies is the BEST choice for non-small–cell lung cancer patients with progressive disease, good performance status, and EFGR-positive tumors?

5. Which of the following BEST describes a partial response to nivolumab therapy?

« Return to Activity

Customers who Purchased
this Activity also Purchased